阿尔茨海默病的病理与创伤性脑病变综合征中的认知,大脑体积和血生物标志物模式的改变有关
Breton M Asken1, Jeremy A Tanner2, Leslie S Gaynor3
1Department of Clinical & Health Psychology, 1Florida Alzheimer's Disease Research Center, University of Florida, 1225 Center Drive, Gainesville, FL, 32610, USA. basken8@phhp.ufl.edu.
Alzheimer's research & therapy
|July 21, 2023
概括
与阿尔茨海默氏症病理学的创伤性脑病症综合征 (TES) 与阿尔茨海默氏症 (AD) 的认知和生物标志物相似. 在TES患者中检测AD生物标志物可能会改善诊断和临床管理.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 生物标志物研究 生物标志物研究
背景情况:
- 创伤性脑病综合征 (TES) 是一种与慢性创伤性脑病 (CTE) 相关的临床诊断,但与阿尔茨海默病 (AD) 有共同的症状.
- 阿尔茨海默病的病理学,如β-粉样蛋白 (Aβ) 斑块,经常与CTE同时发生,使TES诊断复杂化.
- 研究阿尔茨海默氏症神经病理和TES之间的相互作用对于准确的临床病理结论至关重要.
研究的目的:
- 检查阿尔茨海默氏症的神经病理变化如何影响重复头部冲击 (RHI) /TES) 患者的认知,大脑体积和血生物标志物.
- 将RHI/TES患者 (按Aβ状态分层) 的这些变化与临床AD患者和健康对照 (HC) 的变化进行比较.
主要方法:
- 研究了154名参与者:33人患有RHI/TES (Aβ+或Aβ-),62人患有AD,59人患有HC.
- 评估认知能力 (记忆,执行功能等). ),结构性MRI (基于声素的形态测量) 和等离子体生物标志物 (GFAP,NfL,IL-6,IFN-γ,YKL-40).
- 使用ANCOVA来比较组,根据年龄和性别进行调整,专注于中等效果大小 (科恩d>0.50).
主要成果:
- 与Aβ-RHI/TES相比,Aβ+的RHI/TES患者在视觉空间和记忆测试中表现更差.
- 无论是Aβ+还是Aβ-RHI/TES组,均显示中和前叶体积减少,类似于AD患者.
- 与HC和其他组相比,Aβ+RHI/TES的血GFAP升高 (类似于AD),而Aβ-RHI/TES的NfL和IL-6较高.
结论:
- 阿尔茨海默病的病理学显著改变了RHI/TES患者的认知和生物标志物概况.
- 阳性Aβ-PET的RHI/TES患者表现出类似AD患者的认知和生物标志物模式.
- 将阿尔茨海默病生物标志物测量纳入RHI/TES研究可以提高诊断解释和临床管理精度.
关键词:
粉样蛋白是什么 粉样蛋白是什么生物标志物生物标志物脑损伤是因为脑损伤.慢性创伤性脑病变是一种慢性创伤性脑病变.在GFAPAP中,GFAP是最重要的.在 NfL 中,它是NfL.在这里,PET是PET.在等离子体中,我们会得到等离子体.重复发生的头部冲击.创伤性脑病症综合征是什么更多相关视频
12:50Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
Published on: April 14, 2014
40.3K
08:29Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
14.1K
相关概念视频
Alzheimer's Disease: Overview
525
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
525
Dementia
141
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
141
Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219
